T he coxsackie-adenovirus receptor (CAR), a 46-kDa transmembrane protein, was cloned as a common cellular receptor for both viruses. 1, 2 Despite detailed knowledge about the molecular structure and virus interaction of CAR, 3, 4 its biological and possible pathogenic relevance is uncertain. CAR expression, which is relevant for both viral pathogenesis and gene therapy with CAR-dependent vectors, is highly variable among different tissues in various species. 2, 5, 6 Knowledge of CAR localization in the human cardiovascular system at the cellular and subcellular level is limited; however, it is important for understanding the molecular mechanisms of human coxsackievirus 7 and adenovirus infections 8 and the tropism of CAR-dependent viral vectors. Recent work on experimental autoimmune myocarditis in the rat model showed CAR upregulation during myocardial inflammation. 9 We report here on cardiac CAR expression patterns in patients with heart failure due to dilated cardiomyopathy (DCM) or other heart diseases; our data suggest that CAR is dynamically regulated in the human cardiovascular system. We found a low abundance of CAR in normal human myocardium but high cardiac expression of CAR in DCM hearts. Implications for cardiotropic viral infections and therapeutic cardiac gene delivery using CAR-dependent vectors, which has been investigated as a novel approach to the treatment of cardiac disorders, 10 -14 are discussed. We also found that recombinant human CAR (hCAR) expressed in neonatal rat cardiomyocytes was targeted to cell-cell contact sites in a way reminiscent of the CAR expression patterns in DCM hearts, which showed hCAR localized to intercalated discs and sarcolemma. These data, taken together with previous reports that CAR is highly expressed during embryogenesis and is involved in cell-cell recognition, 9, 15 suggest that CAR may be a "pathfinder" protein which is transiently expressed during embryogenesis to promote cell-cell contact formation, that it is strongly downregulated in normal adult human myocardium, and that it may become re-expressed in certain diseases.
Methods

Patients
The clinical data concerning the investigated patients are summarized in the Table. The explanted hearts of 13 patients with terminal heart failure who were undergoing heart transplantation (HTX) were studied. In 8 patients, heart failure was due to DCM; in 3 patients, it was due to coronary artery disease with end-stage ischemic cardiomyopathy; in 1 patient, it was due to familial hypertrophic nonobstructive cardiomyopathy; and in 1 patient, it was due to transposition of the great vessels and atrial and ventricular septal defects. Age at HTX in the 8 DCM patients (1 woman and 7 men) was 52.3Ϯ10.2 years (range, 31.6 to 65.4 years), and left ventricular ejection fraction was 18.9Ϯ3.9% (range, 12% to 25%). Age at HTX in the 5 non-DCM patients (1 woman and 4 men) was 40.9Ϯ14.4 years (range, 26.7 to 60.4 years), and ejection fraction was 19.6Ϯ3.2% (range, 15% to 23%). All patients were in New York Heart Association (NYHA) class 3 to 4 at the time of HTX. Biopsies from 7 explanted donor hearts scheduled for HTX were used as controls (donor group).
Immunohistochemistry, Immunofluorescence, Digital Image Analysis, and Microscopy
Tissue samples were removed from the ventricular septum of cardiomyopathic hearts after explantation. From the donor hearts, endomyocardial biopsies were removed using a bioptome before implantation. All patients gave informed consent. Detailed descriptions of the immunohistochemical, immunofluorescence, digital image analysis, and confocal laser scanning microscopy procedures performed on human tissues and cultured cardiomyocytes can be found in the Data Supplement (located at www.circulationaha.org).
Cardiomyocyte Cultures and Gene Transfer
Cloning a recombinant adenoviral hCAR vector and neonatal rat cardiomyocyte cultures were performed essentially as described previously. 10,16 -18 A detailed description can be found in the Data Supplement.
Statistical Analysis
Details of the statistical procedures performed are in the Data Supplement. 
Overview of the Clinical and Epidemiological Parameters of the Investigated Patients and Donors
ASD indicates atrial septal defect; CAD, coronary artery disease; HCM, hypertrophic cardiomyopathy; TGV, transposition of the great vessels; and VSD, ventricular septal defect.
Results
Expression Patterns of Myocardial CAR Expression in Human Hearts
The clinical characteristics of the patients investigated are summarized in the Table. There were no significant differences between DCM and non-DCM patients with respect to sex, age at HTX, ejection fraction, or NYHA class. When normal human hearts or non-DCM hearts were immunostained for CAR, there was no detectable immunoreactivity on cardiomyocyte sarcolemma or intercalated discs. There was clear immunostaining of interstitial cells ( Figure 1C ), which accounts for the non-zero CAR "area fraction" (defined in the Data Supplement), as determined both in the non-DCM and the donor group ( Figure 2 ). CAR was also detected on vascular smooth muscle cells, but there was no detectable CAR immunoreactivity on the luminal surface of cardiac microvascular endothelium ( Figure 1D ), with no significant differences between the donor, non-DCM, and DCM group. In sharp contrast, there was clear CAR immunostaining on both cardiomyocyte sarcolemma and intercalated discs in 5 of the 8 DCM hearts (62.5%). Conventional immunohistochemistry of this finding is shown in Figure 1A .
The staining of the cardiomyocyte sarcolemma was evident whether the tissues were cross, longitudinally, or traversely cut. When omitting the anti-CAR antibody from the staining procedure, no immunoreactivity was discernible ( Figure 1B ). Quantitation of CAR area fraction ( Figure 2 ) showed significantly (PϽ0.01) higher values in the DCM group (0.0145Ϯ0.0056) than in the non-DCM (0.0013Ϯ0.0006) or donor groups (0.0004Ϯ0.0006). Confocal laser scanning microscopy with single and triple staining for CAR, the integrins ␣ v ␤ 3 and ␣ v ␤ 5 , and CD31 revealed that the CAR immunoreactivity prominent on the intercalated discs and the cardiomyocyte sarcolemma ( Figure 3A) was colocalized with the integrins ␣ v ␤ 3 and ␣ v ␤ 5 ( Figures 3A and B) , which are involved in adenovirus internalization, but not with CD31, which was expressed only by endothelial cells. Furthermore, colocalization of CAR, ␣ v ␤ 3 , and ␣ v ␤ 5 was also observed on interstitial cells, which again were devoid of CD31 reactivity.
In summary, there was significant abundance of myocardial CAR expression in 62.5% of the DCM patients, in whom CAR was colocalized with the integrins ␣ v ␤ 3/5 at the intercalated discs, the sarcolemma, and interstitial cells. CAR was absent from the luminal surface of cardiac microvessels but present in vascular smooth muscle cells and interstitial cells, without significant differences among the 3 groups.
Cellular Targeting of Human CAR in Neonatal Cardiomyocytes
Because normal and non-DCM myocardium showed very low CAR immunoreactivity, re-expression in the DCM myocardium Figure 1 . CAR expression patterns in human hearts by immunohistochemistry. A, Representative CAR expression in a DCM heart (magnification, ϫ200). CAR is expressed on cardiomyocyte sarcolemma, intercalated discs (arrows), and interstitial cells. CAR immunoreactivity of the sarcolemma is clearly present in both crosssectioned and longitudinally sectioned cardiomyocytes. The endocardium is devoid of any CAR expression. B, Same biopsy shown in A was simultaneously subjected to the same immunohistochemical procedure, but the anti-CAR-antibody was omitted from the primary step (magnification, ϫ200). No immunoreactivity is discernible on the cardiomyocyte sarcolemma or on the intercalated discs (arrows), conferring certainty about the specificity of the applied immunoperoxidase method and excluding any cross-reactivity of the anti-mouse EnVision secondary antibody with human heart tissue. C, Representative section of a heart with ischemic cardiomyopathy (magnification, ϫ200). No CAR expression is noticeable on the cardiomyocyte sarcolemma or on intercalated discs. Arrows indicate intercalated discs. Only interstitial cells depict CAR immunoreactivity. Similar staining patterns were observed in both the remaining non-DCM hearts and the donor hearts. D, Intense subendothelial staining of vascular smooth muscle cells in the absence of CAR expression on the luminal endothelial surface in an intramyocardial artery. Arrows indicate vascular endothelium. could possibly follow some embryonic expression pattern. Following this hypothesis, we investigated the cellular targeting of hCAR within neonatal cardiomyocytes using the model of recombinant hCAR expression in neonatal rat cardiomyocytes. Figures 4C and 4D show the distinct hCAR immunoreactivity patterns observed in the cardiomyocyte cultures. No staining of untransfected rat cardiomyocytes was detected ( Figures 4A and  4B ), but hCAR could be detected on transfected cells ( Figures  4C through 4F ). There was strong targeting of hCAR to cell-cell contact sites between cardiomyocytes. This type of targeting was also seen when occasional noncardiomyocytes were present in the cardiomyocyte cultures. Figures 4E and 4F show finger-like structures emanating from a noncardiomyocyte (cardiac fibroblast-like cell) to 2 different cardiomyocytes. Again, CAR immunoreactivity was sharply focused to cell-cell contact sites, which are very small in this case. To further characterize the nature of the described cell-cell contact sites, we looked for possible colocalization and coexpression of CAR and the focal adhesion-associated protein paxillin and the gap junctionassociated protein connexin43, respectively. However, those proteins were neither spatially nor temporally coexpressed; they follow clearly distinct expression patterns (data not shown).
Enhancement of Adenoviral Infection by CAR Overexpression
By overexpressing human CAR in the cardiomyocytes, adenovirus attachment to and uptake into the cells was strongly enhanced ( Figure I in Data Supplement), suggesting that CAR is a key determinant of cardiac susceptibility to adenovirus infections, with the coreceptors ␣ v ␤ 3 and ␣ v ␤ 5 not being a limiting factor.
Discussion Highly Variable CAR Expression Patterns in Human Hearts
CAR is used by 2 unrelated viruses as a common cellular receptor, 1,2 but its physiological role at the cellular level and its possible pathogenic relevance are currently unknown. Our findings of highly variable CAR expression patterns in normal versus diseased human myocardium and of specific cellular CAR targeting in cardiomyocyte cultures lead to the following 2 hypotheses: (1) the low abundance of CAR in normal and non-DCM human hearts may render them rather resistant to infection by CAR-dependent viruses, whereas CAR upregulation may be an important predisposing factor for CAR-dependent viral infections of the human myocardium; and (2) CAR may play important physiological and biological roles in cell-cell contact formation between cardiomyocytes, consistent with the findings both in human tissues and in cardiomyocyte cultures.
Possible Causes and Pathogenic Consequences of Altered CAR Expression
Although interstitial cells expressed CAR in both DCM and control hearts, CAR expression in cardiomyocytes was absent from donor hearts and hearts from patients with terminal heart failure entities other than DCM; instead, it was significantly induced in the cardiomyocytes of DCM hearts. The presence of CAR in cardiomyocytes was observed in 62.5% of the investigated DCM hearts. This staining pattern was demonstrated by both immunohistochemical and immunofluorescence techniques. Technical pitfalls, such as cross-reactivity of the antimouse antibody applied in immunohistochemistry or crossbinding fluorophores in immunofluorescence, were excluded: tissues stained omitting the anti-CAR antibody did not display any immunoreactivity, no cross-staining of the fluorescent dyes was observed when modifying the sequence of staining, and the anti-CD31 antibody clearly depicted exclusive staining of endothelium and no interference with CAR. Whether there is "acquired" up-regulation of CAR from a low basal level or if some individuals maintain permanent high CAR levels on a genetic basis cannot be decided thus far, but the latter could predispose such individuals for cardiac disease.
Given the limited number of hearts examined, no definitive generalization is currently possible about the possible disease specificity of this phenomenon. Interestingly, however, although myocardial failure itself or pharmacological treatments of heart failure may cause alterations in cardiac structure, elevated CAR expression was not observed in heart failure entities other than DCM, in contrast with other alterations of myocardial structure and function associated with heart failure of various origins. 19 -23 Our findings may reflect a predisposing mechanism for cardiotropic viral infections in DCM hearts. However, CAR induction in cardiomyocytes has been reported in rat autoimmune myocarditis after the onset of infiltration by inflammatory cells. 9 CAR upregulation triggered by nonviral factors may predispose for secondary viral infection, or primary viral infection may induce CAR upregulation. To establish such cause-effect relationships in humans, further studies on the relative time courses of CAR expression, virus load, and inflammation in human myocarditis are required.
Considering the possible pathogenic relevance of CAR regulation in humans, the absence of CAR from the luminal vascular surface and the low abundance in normal myocardium should render the normal human heart rather resistant to CAR-dependent viral infections. Although adenovirus infection is common, viral myocarditis due to adenoviruses is uncommon. 24, 25 Because adenovirus myocarditis occurs both in children and adults, 8 the question for "cardiac" predisposing factors facilitating adenovirus access to the human heart is of considerable interest. In cultured cardiomyocytes, we have shown directly that hCAR overexpression promotes very efficient adenovirus entry into these cells ( Figure I in Data Supplement).
We propose that certain, as yet unknown factors (such as cytokines) upregulate CAR on human myocardium and that the level of this upregulation of the attachment receptor CAR 26 is a major determinant of susceptibility to cardiac infection by adenoviruses and coxsackieviruses. The adenovirus coreceptors ␣ v ␤ 3 and ␣ v ␤ 5 27,28 are present in equal amounts on both normal and diseased myocardium and are less likely to be key determinants. Because CAR is not only the attachment receptor for adenoviruses, but it also serves as a receptor for coxsackieviruses, 1,2 CAR may be similarly important for both of these otherwise unrelated viruses. Identification of the trigger factors that lead to CAR overexpression in the human heart is of considerable interest, and ablation of CAR-virus interaction 3 may have therapeutic potential.
Expression Patterns and the Biological Role of CAR
Another hypothesis consistent with the data presented here concerns the normal biological role of CAR. Recombinant human CAR expressed in neonatal cardiomyocytes shows a very distinct preference for targeting to sites of cell-cell contact formation. Not only is CAR condensed at cell-cell boundaries between cardiomyocytes, but it is also at contact sites between cardiomyocytes and between cardiomyocytes and noncardiac cells. CAR may serve as a pathfinder protein expressed during embryogenesis to promote cardiac tissue formation that is then no longer needed to stabilize specialized cell-cell contacts. The hypothesis that CAR is a pathfinder protein explains the low CAR abundance in the adult, already well-structured heart as the expected normal state, whereas the observed CAR upregulation would be interpreted as part of an embryonic gene re-expression pattern generally seen in severe heart failure. This would not necessarily have adverse consequences in the case of CAR, but because of its nonphysiological role as a receptor for 2 viruses, the upregulation could have adverse consequences if a virus load is put on the patient. Given the low abundance of CAR in normal human myocardium, an essential role of CAR in maintaining the structural integrity of the adult myocardium seems unlikely, as opposed to a number of cytoskeletal, linkage, and extracellular proteins whose expression is dysregulated in failing human myocardium. 18, 27, 28 However, upregulation of the putative pathfinder protein CAR may reflect an attempt of the organism at tissue repair by reestablishment of cell-cell contacts in a progressively dilating myocardium.
CAR-dependent vectors in man. This is reminiscent of the situation in human airways, where restriction of CAR expression to the basolateral surfaces of the airway epithelium has been an obstacle to adenovirus-mediated gene therapy of cystic fibrosis. 29 -31 We found that CAR was expressed in subendothelial layers of the vessel wall; other investigators have reported the absence of CAR in the vessel wall of neonatal rats. These differences may reflect differences between tissues from neonatal rats and those from adult humans; alternatively, they may reflect differences in antibody specificity. Consequences of asymmetric CAR expression in the vascular wall for gene transfer need to be investigated further. Low basal CAR expression on the cardiomyocytes themselves may also limit adenoviral gene transfer, because the receptor complement on these target cells is incomplete. The influence of disease-associated or deliberately induced alterations of CAR expression on the efficiency and cellular targeting of myocardial gene transfer deserves attention.
